

LETTER OF INTENT

From: SEON KEE KIM

Attention: **Ms. Mi Jung Sung, CEO, HAIM BIO Co., Ltd.**

January 4th , 2024

Subject: **Expression of Intent to Support Haim Bio Phase II Clinical Trial Funding**

Dear Ms. Sung

We have been closely monitoring Haim Bio's strides in developing groundbreaking anti-cancer drugs. The potential for collaboration between our entities is striking, and we are eager to forge a strong partnership with your company. This Letter of Intent ("LOI") signifies our unwavering commitment to participating in:

1. Contributing to Haim Bio USA's \$15 million funding round for gastric and lung cancer applications in the USA post-Phase II(a) clinical trials.
2. Haim Bio KOREA's funding endeavors for brain and pancreatic cancer clinical trials in Korea.
3. Amount of invest in Haim Bio Korea will be determined by estimation of Phase II Clinical Trial. (Approximately \$10 million)

Our intent is rooted in the profound respect for the extensive work Haim Bio has devoted to cancer treatment technologies. Your steadfast dedication has laid a crucial foundation in an area we perceive as pivotal for healthcare advancement, particularly in cancer-related treatments.

Warm regards,

On behalf of Haim Bio USA

SEONKEE KIM
Managing Director

